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A range of schedules are recommended for hepatitis B vaccination of premature infants. This open-label study (217744/083)
compared the immune response of premature (N = 94) and full-term infants (N = 92) to hepatitis B antigen following
primary administration of hexavalent DTPa-HBV-IPV/Hib vaccine at 2–4–6 months and a booster dose at 18 months. Anti-
HBsAgantibodiesweredeterminedbeforeandonemonthafterprimaryandboosterdoses.Therewerenosigniﬁcantdiﬀerencesin
postprimary seroprotection rates (anti-HBsAg >10mIU/mL; preterm 93.4%; full-term 95.2%) or geometric mean concentrations
(634 versus 867mIU/ml), and neither appeared to be related to gestational length or birth weight. Prebooster seroprotection
rates were 75 and 80.6%, respectively. Six premature infants did not respond to primary and booster doses. Primary and booster
vaccinations with DTPa-HBV-IPV/Hib elicit satisfactory anti-HBsAg responses in preterm infants, which are not inﬂuenced by
gestational age or birth weight. This schedule and vaccine will greatly facilitate the immunisation of premature infants.
1.Introduction
Infection with hepatitis B virus (HBV) persists as a world-
wide public health problem, with vertical transmission of
HBVbeingresponsibleforapproximatelyonethirdofallnew
cases of hepatitis B. Childhood hepatitis B immunisation has
signiﬁcantly reduced the incidence and prevalence of HBV
infection[1],andcurrentlymorethan160countriesusehep-
atitis B vaccine in their national immunisation programmes.
Exciting new global initiatives have been implemented that
allowthepoorestcountriesintheworldtoaﬀordthisvaccine
[2].
The number of infants born prematurely has risen
in the last 15 years, and recent advances in the care of
premature infants have substantially increased their survival
rates [3]. It is now thought that prematurity, rather than a
speciﬁc gestational age or birth weight, is more predictive
of immunologic HBV response compared with full-term
infants. The latest recommendation is that medically stable
preterm or low-birth weight babies (weighing >2000g) who
are born to hepatitis B surface antigen (HBsAg) negative
mothers should receive HBV at birth or shortly thereafter.
[4].
Concern among parents and paediatricians about the
number of injections required during each immunisation
visit has contributed to the observation that routine paedi-
atric vaccination is often delayed in preterm infants [5, 6].
However, several combined vaccines are now available which
reduce the required number of injections and medical visits.
The acceptability of multiple immunisations and increasing
the coverage of each vaccine can thereby be achieved.
We have previously shown preterm infants less than
37 weeks of gestational age to display satisfactory immune
response to all component antigens of a hexavalent2 Infectious Diseases in Obstetrics and Gynecology
diphtheria-tetanus-acellular pertussis-hepatitis B-inacti-
vated poliovirus-Haemophilus inﬂuenzae type B vaccine
(DTPa-HBV-IPV/Hib), with seroprotection/vaccine resp-
onse rates generally similar to those seen in full-term infants
following primary vaccination and a booster dose [7–9].
This paper details the results of a further analysis of the
immune response in the preterm cohort to the hepatitis B
component of this hexavalent vaccine, including a follow-up
at 18 months and a speciﬁc focus on the nonresponders.
2.MaterialsandMethods
2.1. Study Design. This was an open-label study with two
parallel groups: preterm subjects (<37 weeks’ gestation) and
a control group of full-term infants. The study protocol was
approved by the Clinical Investigation Research Board of
La Paz Hospital and conducted in accordance with Good
Clinical Practice Guidelines. Written informed consent was
obtained from the parents or guardians of all subjects prior
to enrolment. Trial number: 217744/083 (DTPa-HBV-IPV-
083).
2.2. Subjects. Preterm subjects were stratiﬁed according to
clinical characteristics including length of gestation, birth
weight,pre-andpostnatalsteroiduse,needforredbloodcell
transfusion, and weight at 6 months. Length of gestation was
determined by date of the last menstrual period and/or early
ultrasound scan and subsequently conﬁrmed by neonatal
examination. Exclusion criteria comprised major congenital
defectsorseriouschronicillnesses,severeneurologicdamage
or nontreatable convulsions; known or suspected immune
dysfunction, HIV positive or hepatitis B surface antigen
(HBsAg) positive mother, acute disease or rectal temperature
≥38◦C (immunization deferred), a history of allergic reac-
tion to any of the vaccine components, apnea episode within
7 days of vaccination, steroid therapy 30 days before the ﬁrst
vaccine dose, any immunoglobulin therapy within 2 months
before enrollment or during the trial, administration of any
vaccine or experimental drug or vaccine during the 30 days
after/before the administration of the study vaccine.
2.3. Vaccines. A l ls u b j e c t sw e r ep r i m e dw i t haD T P a - H B V -
IPV/Hib vaccine [Infanrix hexa, GlaxoSmithKline (GSK)
Biologicals, Rixensart, Belgium] at 2, 4, and 6 months and
receivedaboosterdosewiththesamevaccineat18monthsof
age. The vaccine was administered as a 0.5mL intramuscular
injection into the right anterolateral thigh.
EachdoseofDTPa-HBV-IPV/Hibvaccinecontained ≥30
international units (IU) of diphtheria toxoid, ≥40 IU of
tetanus toxoid, 25µg of adsorbed pertussis toxin, 25µgo f
adsorbed ﬁlamentous hemagglutinin, 8µgo fa d s o r b e dp e r -
tactin, 10µg of HBsAg, 40, 8, and 32 D-antigen units of polio
virus types 1, 2, and 3, respectively, and 0.7mg of aluminum
as salts. The lyophilized Hib vaccine pellet contained 10µg
of Haemophilus inﬂuenzae type b polysaccharide conjugated
to 20 to 40µg of tetanus toxoid, 0.12mg of aluminium
phosphate, and 10mg of lactose.
For infants not responding to primary and booster doses
(anti-HBs<10mIU/mL),threefurther10µgdosesofhepati-
tisBrecombinantvaccine(Engerix-B;GSKBiologicals)could
be administered in the third year of life. If the anti-HBs titre
was above 100mIU/mL after the second additional dose (6th
in total), then the third dose was not given. If it was below
100mIU/mL, then the third dose was administered.
2.4. Immunogenicity Analysis. Blood samples were drawn
beforetheﬁrstdoseandonemonthafterthethirdinprimary
course and before and one month after the booster dose.
Serum samples were stored at −20
◦C until analysis at GSK
Biologicals. Antibodies against HBV were determined using
ELISA (enzyme-linked immunosorbent assay), with an assay
cut-oﬀ of 10mIU/mL for HBsAg.
2.5. Statistical Analysis. Statistical analysis of the immuno-
genicity results was performed on the according-to-protocol
(ATP) cohort. Seroprotection rates and antibody geometric
mean concentrations (GMCs) were calculated with exact
95%conﬁdenceintervals(CI)ateachtimepoint.Diﬀerences
in seroprotection rates between the preterm and full-term
groups were compared using Fisher’s exact test.
3. Results
A total of 186 infants were enrolled (94 preterm and 92 full-
term), of whom 93 and 89 infants, respectively complied
with the criteria for inclusion in the ATP cohort for analysis
of immunogenicity of the primary vaccination course. The
demographic and neonatal characteristics of the infants have
been previously described [7] . The mean age at the time of
ﬁrst immunisation was 8.6 ± 0.63 weeks (range 8–11 weeks)
and 8.2 ± 0.8 (range 6–11 weeks), respectively.
Of the 155 infants who received booster doses, 152
subjects were included in the ATP cohort for analysis of
immunogenicity of the booster dose (84 prematurely born
subjects and 68 full-term subjects). Mean age at the time
of booster vaccination was 18.2 ± 0.47 months (range 18–
20 months) and 18.3 ± 0.55 months (range 18–20 months),
respectively.
3.1. Postprimary Immunogenicity Results. The mean im-
munogenicity data after primary course and before and after
booster dose are included in Table 1. A total of 93.4% of
the preterm and 95.2% of the full-term infants responded to
primary vaccination (anti-HBs ≥10 mIU/mL). Although the
GMCsaftertheprimarycoursewerenumericallylowerinthe
preterm group, the diﬀerences were not signiﬁcant.
The immunogenicity results by gestational age are shown
in Table 2. All subjects with a gestation below 31 weeks
were seroprotected compared with 83.3% and 92.6% in
the groups with a higher gestational age. However, with
respect to GMCs, a numerically higher response was seen
in the groups aged 34–36 weeks and 28–30 weeks but the
diﬀerences were not signiﬁcantly diﬀerent. After the booster
dose, the seroprotection rates were lower for the groups withInfectious Diseases in Obstetrics and Gynecology 3
Table 1: Anti- HBs seroprotection rates and GMCs in preterm and full-term infants one month after the primary course and before and
after the booster dose (ATP cohort for immunogenicity).
Seroprotection GMC
Nn % 95% CI mIU/ml 95% CI
Postprimary
Preterm 91 85 93.4 86.2–97.5 634.1 433.8–927.0
Full-term 84 80 95.2 88.3–98.7 867.1 576.6–1303.9
Prebooster
Preterm 84 63 75.0 64.4–83.8 56.8 39.6–81.4
Full-term 67 54 80.6 69.1–89.2 58.1 39.1–86.3
Postbooster
Preterm 83 76 91.6 83.4–96.5 1771.0 1060.3–2958.1
Full-term 68 67 98.5 92.1–100.0 1965.0 1180.1–3272.0
Table 2: Anti-HBs seroprotection rates (SR) and geometric mean concentrations (GMC) by subgroup of preterm infants after primary
course and booster dose (ATP cohort for immunogenicity).
Seroprotection GMC
Gestational age (weeks) Nn % 95% CI mIU/ml 95% CI
Primary course
34–36 27 25 92.6 75.7–99.1 955.9 461.1–1981.8
31–33 24 20 83.3 62.6–95.3 418.0 153.7–1136.4
28–30 20 20 100 83.2–100 1044.5 633.9–1721
24–27 20 20 100 83.2–100 364.8 184.5–721.5
Booster dose
34–36 24 22 91.7 73.0–99.0 2389.1 919.4–6207.9
31–33 23 18 78.3 56.3–92.5 1127.2 262.2–4845.2
28–30 18 18 100 81.5–100 3555.9 1881.1–6721.8
24–27 18 18 100 81.5–100 1054.0 508.6–2184.2
higher gestational age but GMCs retained a similar pattern
to that observed after the primary course.
A nonconsistent response was also seen in the analysis
according to birth weight (Table 3), where 92% of subjects
with the lowest birth weight were protected compared with
allbabieswithbirthweight1000–1500g.Only82.4%ofthose
weighing more than 2000g at birth were seroprotected. No
speciﬁc pattern of GMC response was observed. Similarly,
there was no signiﬁcant diﬀerence according to babies with
(N = 15) or without (N = 76) intrauterine growth restriction
(seroprotection rates: 86.6 and 94.7%, resp.), or with (N =
67) or without (N = 24) prenatal steroids (seroprotection
rates: 91 and 100%, resp.).
Post-primary anti-HBs seroprotection rates and GMCs
werenumericallylowerintheninesubjectswhohadreceived
postnatal steroids (88.9% and 188.1, resp.) than the 81
subjectswhohadnotreceivedthem(93.9%and724.6,resp.),
but the diﬀerences were not signiﬁcant.
Blood transfusion during the neonatal period did
not signiﬁcantly aﬀect seroprotection rates (anti-HBs ≥10
mIU/mL) or GMCs [transfused infants: 94.7% (95% CI
82.3–99.4) and 486.6 (95% CI 280.0–845.5) mIU/ml, respec-
tively; no transfusion: 92% (95% CI 81.8–97.9) and 766.8
(95% CI 542.8–1298.7) mIU/mL, resp.) in all babies.
Considering weight at 2 and 6 months as a variable inde-
pendent of gestational age and birth weight, no signiﬁcant
patterns of diﬀerences were observed in seroprotection rates
(Table 4).
3.2. Prebooster Persistence and Booster Response. Before the
booster dose, both the seroprotection rates of anti-HBs
GMCs were low in both the pre- and full-term groups
(Table 1).Seroprotectionroseto91.6and98.5%,respectively
one month after the booster dose and the GMCs increased
to 1771 and 1965 mIU/mL, respectively. There were no
signiﬁcant diﬀerences between the responses in the preterm
and full-term groups.
3.3. Nonresponders. Six preterm infants (6.59%) did not
respond to primary immunisation and also failed to respond
to the booster dose (anti-HBs ≥10 mIU/mL; Table 5). All
of these infants had a gestational age above 31 weeks. Two
babies weighed less than 1000g at birth and had severe
intrauterine growth restriction (IUGR; 32 weeks/600g and
31 weeks/800g), but the other four babies did not have any
risk factors.
One infant responded to the 5th HBV dose, two to the
6th,andonetothe7th.Twobabies(2.19%)neverresponded.4 Infectious Diseases in Obstetrics and Gynecology
Table 3: Post-primary anti-HBs seroprotection rates and GMCs by birth weight (ATP cohort for immunogenicity).
Seroprotection GMC
Birth weight (kg) Nn % 95% CI mIU/ml 95% CI
≥2.0 17 14 82.4 156.6–96.2 493.9 147.2–1657.0
≥1.5<2.0 23 22 95.7 78.1– 99.9 933.8 418.8–2081.8
≥1.0<1.5 26 26 100 86.8–100 1294.5 882.5–1898.6
<1.0 25 23 92.0 74.0–99.0 250.7 122.0–515.1
Table 4: Post-primary anti-HBs seroprotection rates and GMCs by weight at vaccination and percentile weight at six months (ATP cohort
for immunogenicity).
Seroprotection GMC
Nn % 95% CI mIU/ml 95% CI
Weight at ﬁrst vaccination (kg)
≥4 19 16 84.2 60.4–96.6 617.4 206.8–1843.8
≥3<4 26 25 96.2 80.4–99.9 984.0 479.0–2021.6
≥2<3 26 26 100 86.8–100 972.6 589.2–1605.3
<2 20 18 90.0 68.3–98.8 210.7 95.4–465.2
Percentile weight at six months
>50 29 27 93.1 77.2–99.2 1140.8 577.6–2253.1
>25 ≤50 21 20 95.2 76.2–99.9 353.7 150.8–829.4
>10≤25 14 13 92.9 66.1–99.8 561.4 205.7–1532.4
≤10 27 25 92.6 75.7–99.1 566.2 280.0–1144.7
Table 5: Anti-HBs concentrations (mIU/ml) after all HBV doses in subjects who were non-responders to hepatitis B at the end of the
primary and booster studies.
Post Extra HBV HBV
Gestational
age (Weeks)
Birth
weight
(kg)
Percentile
at birth
Weight at 1st
vaccination
(kg)
Percentile
at 6
months
Weight at
6m o n t h s
(kg)
Pre-
primary
Post-
primary
Pre-
booster
Post-
booster
Dose
1
Dose
2
Dose
3
Persistence
at 4 years
(mIU/ml)
33 2.1 75 4.4 95 8.3 <10 <10 <10 <10 690 3485 NG 176
35 2.0 25 4 25 6.7 <10 <10 <10 <10 <10 <10 32 128
32 0.6 <10 1.7 <54 . 4 <10 <10 <10 <10 <10 141 NG 64
31 0.8 <10 1.7 10 5.1 97 <10 <10 <10 <10 NA NG <10
33 2.0 50 4.3 >90 8.4 <10 <10 <10 <10 <10 <10 <10 <10
35 1.7 10 3.6 50 6.6 <10 <10 <10 <10 <10 1087 NG NA
NA = Not available; NG = Not given.
One was an infant with IUGR who had anti-HBs antibodies
before vaccination and the other although born prematurely
at 33 weeks weighed 2000g and did not have risk factors.
These 6 infants did show a good response to the other
antigens included in the DTPa-HBV-IPV/Hib vaccine.
4. Discussion
The American Academy of Pediatrics (AAP) recommends
that all infants receive hepatitis B vaccine at birth or before
discharge from the hospital. In infants weighing less than
2000g and born to HbsAg negative mothers, the ﬁrst dose
of hepatitis B vaccine is recommended at 30 days [4].
Immunogenicitystudiesindicatethatprematurechildren
generally respond less well to hepatitis B vaccination than
full-term infants, both in terms of seroprotection rates [10–
15] and GMCs [14, 16–21]. Our results are consistent with
these ﬁndings, although the seroprotection rate in preterm
subjects was not signiﬁcantly diﬀerent to that in full-term
subjects.
Analysis according to birth weight in premature infants
hassuggestedarelationshipbetweenreducedimmunological
response and low birth weight [16, 20, 22, 23]. Interestingly,
in our study, babies under 1000g achieved higher seropro-
tection rates than those children with a birth weight in excess
of 2000g, but their GMC response was lower.Infectious Diseases in Obstetrics and Gynecology 5
Gestational age seems to be a much more objective
parameter than weight for assessing immune response in
premature babies. After birth dosing, both seroprotection
rates and GMCs are generally lower in babies with a reduced
gestational age [16, 20, 21, 23] but this trend reverses as the
chronologicalageatthetimeofstartingvaccinationincreases
[24].Inourstudy,allchildrenwithagestationalagebelow31
weeks responded to immunisation in the two groups with a
greater gestational age. The response in terms of GMCs was
however irregular.
Our ﬁndings strengthen the notion that the immunolog-
ical response in premature babies depends on postnatal age
of vaccination and not on birth weight or gestational age.
Indeed, studies in term infants have demonstrated that very
young infants (up to 2 months) achieve lower GMCs after
three doses of hepatitis B vaccine compared to infants who
are at least 3 months of age at the time of ﬁrst vaccination
[25].
Low-birth weight has been reported to be associated
with an inadequate immune response to early hepatitis B
vaccination in premature infants by some workers [16], but
others have either shown no eﬀect [19] or the opposite [26].
Similar anomalies have been seen when considering gesta-
tional age [19, 26] and the postnatal use of corticosteroids
[16, 26, 27]. In our study all of the nonresponders had
a gestational age of at least 31 weeks and, except for two
babies with severe IUGR, were of appropriate weight. Nine
infants received postnatal corticosteroids and although they
responded to a lesser extent to hepatitis B vaccination, the
diﬀerences were not signiﬁcant. Only one of these babies
was a non-responder. Two children in our cohort received
transfusions (1 or 6) in the neonatal period, coinciding with
severe intrauterine restriction, but no diﬀerences in response
were identiﬁed between the transfused and nontransfused
infants.
Other factors linked to nonresponse to hepatitis B vac-
cination in premature babies include hyperbilirubinaemia
[28], sepsis [16, 19, 26], and the presence of speciﬁc
antibodies transferred by the mother through the placenta.
All of the children in our study who did not respond to
HBsAg developed jaundice, but all were within physiological
limits for bilirubin. Sepsis was recorded in only one of
the infants classiﬁed as a non-responder. Only one of
our non-responding babies had prior antibodies, but in
conjunction with severe intrauterine restriction and the
receipt of multiple transfusions.
We found no diﬀerences in immune response in the
infants with either IUGR, or in the diﬀerent groups stratiﬁed
according to percentile weight at 6 months, consistent with
previous ﬁndings [15, 17]. However, at the time of vaccine
initiation, GMCs were lower in those children who weighed
less than 2kg but this is logical given that they were smaller
at birth.
Three doses of HB vaccines are generally recommended
in preterm babies, although 4 doses have been suggested
[10, 15, 17, 22, 29, 30], as well as an antibody test after the
third to assess the suitability of a booster dose [19, 20, 22].
In a study of 29 preterm infants who were non-responders,
14 received additional doses of vaccine; 7 seroconverted after
the ﬁrst additional dose, 3 required a second additional dose
and 1 required a third [16]. In another study although only
three of the nine non-responding pre-term infants returned
for a fourth vaccine dose, all subsequently seroconverted
[26]. We decided to administer 4 doses, but according to the
schedule recommended for full-term babies, and include a
booster dose at 18 months with the hexavalent vaccine used
for primary vaccination. All six infants that did not respond
totheprimarycoursealsodidnotrespondtoafourthdose;1
infant responded to the ﬁfth, 2 to the sixth, and 1 after seven
doses. Only two infants remained non-responders.
Few authors have studied the persistence of anti-HBs in
premature infants; however, Kesler et al. [27] reported that
similar declines in antibody titres are seen in pre-term and
full-term babies after primary vaccination, although preterm
infants generally have a lower titre. We found similar results
prior to the booster dose and observed a good immune
response with similar GMCs among preterm and full-term
infants after the booster.
Many long-term studies of infants indicate that immuni-
sation against hepatitis B induces both antibody-producing-
cells and memory cells, and the rapid development of
anamnestic responses [31]. Booster doses of vaccine do
not seem necessary to ensure long-term protection [32–
34], although some factors might be important. Delaying
vaccination until infants achieve a weight of 2000g results in
a signiﬁcantly higher GMC at 3-3.5 year of age as compared
to early vaccination in both pre- and full-term infants [35].
Most children vaccinated at birth retain immunological
memory to hepatitis B vaccine for 15 years, but those
who did not were more likely to have received HB IG
immunoglobulin at birth, suggesting that passive antibody
may interfere with the induction of immunological memory
[36].
In summary, preterm babies born to HBsAg-negative
mothers and vaccinated with a hexavalent DTPa-HBV-
IPV/Hib vaccine at 2, 4, and 6 months responded well
immunologically and similarly to children born at full term.
The response in terms of seroprotection rates was not
inﬂuenced either by gestational age or birth weight, and
these ﬁndings strengthen the notion that the immunological
response in premature babies depends on postnatal age and
not on birth weight or gestational age. Six infants, all with
a gestation age above 31 weeks, did not respond, but we
did not ﬁnd any associated risk factors, other than severe
intrauterine malnutrition in two babies. After a further
vaccination cycle, only 2 remained “true” non-responders.
The vaccination schedule used here for preterm babies born
to HBsAg-negative mothers oﬀers a single schedule for all
infants, with fewer injections and better acceptance.
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